Triple-negative breast cancer: Bridging the gap from cancer genomics to predictive biomarkers

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 3, 2014, Pages 88-100

  Davis, S Lindsey ^a   Eckhardt, S Gail ^a   Tentler, John J ^a   Diamond, Jennifer R ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

biomarkers; targeted therapy; triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CISPLATIN; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 1; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEOSIDE DIPHOSPHATE KINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN;

APOPTOSIS; BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; DNA METHYLATION; DNA STRAND BREAKAGE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOHISTOCHEMISTRY; NONSENSE MUTATION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 84899010273     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834013519843     Document Type: Review

References (60)

1. Abkevich V. Timms K. Hennessy B. Potter J. Carey M. Meyer L. et al. (2012) Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107: 1776–1782.
2. Banerjee S. Reis-Filho J. Ashley S. Steele D. Ashworth A. Lakhani S. et al. (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59: 729–735.
3. Bauer K. Brown M. Cress R. Parise C. Caggiano V. (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109: 1721–1728.
4. Bidard F. Matthieu M. Chollet P. Raoefils I. Abrial C. Domont J. et al. (2008) P 53 status and efficacy of primary anthracyclines / alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 19: 1261–1265.
5. Byrski T. Gronwald J. Huzarski T. Grzybowska E. Budryk M. Stawicka M. et al. (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375–379.
6. Carey L. Winer E. Viale G. Cameron D. Gianni L. (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683–692.
7. Chavez-Macgregor M. Gonzalez-Angulo A.M. (2012) Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 21: 1835–1843.
8. Cheang M. Voduc D. Bajdik C. Leung S. Mckinney S. Chia S. et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368–1376.
9. Curtis C. Shah S. Chin S. Turashvili G. Rueda O. Dunning M. et al. (2012) The Genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346–352.
10. Daemen A. Wolf D. Korkola J. Griffith O. Frankum J. Brough R. et al. (2012) Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 135: 505–517.
11. Darb-Esfahani S. Kronenwett R. von Minckwitz G. Denkert C. Gehrmann M. Rody A. et al. (2012) Thymosin beta 15a (TMSB15a) is a predictor of chemotherapy response in triple-negative breast cancer. Br J Cancer 107: 1892–1900.
12. de Ruijter T. Veeck J. de Hoon J. van Engeland M. Tjan-Heijnen V.C. (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137: 183–192.
13. Dennison J. Molina J. Mitra S. Gonzalez-Angulo A. Balko J. Kuba M. et al. (2013) Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 19: 3703–3713.
14. Dent R. Trudeau M. Pritchard K. Hanna W. Kahn H. Sawka C. et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429–4434.
15. Diamond J. Eckhardt S. Tan A. Newton T. Selby H. Brunkow K. et al. (2013) Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res 19: 291–303.
16. Ellard S. Clemons M. Gelmon K. Norris B. Kennecke H. Chia S. et al. (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent / metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27: 4536–4541.
17. Esserman L. Berry D. Cheang M. Yau C. Perou C. Carey L. et al. (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-Spy 1 trial (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132: 1049–1062.
18. Farmer H. McCabe N. Lord C. Tutt A. Johnson D. Richardson T. et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917–921.
19. Finn R. Bengala C. Ibrahim N. Roche H. Sparano J. Strauss L. et al. (2011) Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17: 6905–6913.
20. Finn R. Dering J. Ginther C. Wilson C. Glaspy P. Tchekmedyian N. et al. (2007) Dasatinib, an orally active small molecule inhibitor of both the Src and Abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319–326.
21. Fong P. Boss D. Yap T. Tutt A. Wu P. Mergui-Roelvink M. et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123–134.
22. Foulkes W. Smith I. Reis-Filho J. (2010) Triple-negative breast cancer. N Engl J Med 363: 1938–1948.
23. Gelmon K. Tischkowitz M. Mackay H. Swenerton K. Robidoux A. Tonkin K. et al. (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852–861.
24. Gonzalez-Angulo A. Timms K. Liu S. Chen H. Litton J. Potter J. et al. (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17: 1082–1089.
25. Gordon V. Banerji S. (2013) Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res 19: 3738–3744.
26. Grob T. Heilenkotter U. Geist S. Paluchowski P. Wilke C. Jaenicke F. et al. (2012) Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat 134: 561–567.
27. Gucalp A. Traina T.A. (2010) Triple-negative breast cancer: role of the androgen receptor. Cancer J 16: 62–65.
28. Huang F. Reeves K. Han X. Fairchild C. Platero S. Wong T. et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226–2238.
29. Jacquemier J. Boher J. Roche H. Esterni B. Serin D. Kerbrat P. et al. (2011) Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res 13: R109.
30. Jing J. Greshock J. Holbrook J. Gilmartin A. Zhang X. Mcneil E. et al. (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11: 720–729.
31. Joosse S. van Beers E. Tielen I. Horlings H. Peterse J. Hoogerbrugge N. et al. (2009) Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with ARRAY-CGH. Breast Cancer Res Treat 116: 479–489.
32. Kashiwagi S. Yashiro M. Takashima T. Aomatsu N. Ikeda K. Ogawa Y. et al. (2011) Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 13: R122.
33. Keam B. Im S. Lee K. Han S. Oh D. Kim J. et al. (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13: R22.
34. Kraus J. Beriwal S. Dabbs D. Ahrendt G. McGuire K. Johnson R. et al. (2012) Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma. Appl Immunohistochem Mol Morphol 20: 334–339.
35. Lakhani S. Reis-Filho J. Fulford L. Penault-Llorca F. van der Vijver M. Parry S. et al. (2005) Prediction of BRCA 1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11: 5175–5180.
36. Lee S. Choi Y. Park Y. Kim S. Cho E. Ahn J. et al. (2011) Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 68: 743–751.
37. Lehmann B. Bauer J. Chen X. Sanders M. Chakravarthy A. Shyr Y. et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750–2767.
38. Lehmann B. Pietenpol J. (2012) Targeting mutant P 53 in human tumors. J Clin Oncol 30: 3648–3650.
39. Lehmann S. Bykov V. Ali D. Andren O. Cherif H. Tidefelt U. et al. (2012) Targeting P 53 in vivo: a first-in-human study with P53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30: 3633–3639.
40. Li X. Liu M. Zhang Y. Wang J. Zheng Y. Li J. et al. (2011) CK5/6, EGFR, Ki-67, cyclin D1, and NM23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol 28(Suppl. 1): S129–S134.
41. Liedtke C. Mazouni C. Hess K. Andre F. Tordai A. Mejia J. et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275–1281.
42. Mateo J. Ong M. Tan D. Gonzalez M. de Bono J. (2013) Appraising iniparib, the PARP inhibitor that never was - what must we learn? Nat Rev Clin Oncol, in press.
43. Mavaddat N. Barrowdale D. Andrulis I. Domchek S. Eccles D. Nevanlinna H. et al. (2012) Pathology of breast and ovarian cancers among BRCA 1 and BRCA 2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21: 134–147.
44. Metzger-Filho O. Tutt A. de Azambuja E. Saini K. Viale G. Loi S. et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30: 1879–1887.
45. Oakman C. Viale G. Di Leo A. (2010) Management of triple negative breast cancer. Breast 19: 312–321.
46. Ono M. Tsuda H. Shimizu C. Yamamoto S. Shibata T. Yamamoto H. et al. (2012) Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 132: 793–805.
47. Peppercorn J. Perou C. Carey L. (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26: 1–10.
48. Rakha E. El-Sayed M. Green A. Lee A. Robertson J. Ellis I. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25–32.
49. Rakha E. Ellis I. (2009) Triple-negative/basal-like breast cancer: review. Pathology 41: 40–47.
50. Reis-Filho J. Tutt A. (2008) Triple negative tumours: a critical review. Histopathology 52: 108–118.
51. Shah S. Roth A. Goya R. Oloumi A. Ha G. Zhao Y. et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–399.
52. Silver D. Richardson A. Eklund A. Wang Z. Szallasi Z. Li Q. et al. (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145–1153.
53. Stephens P. Tarpey P. Davies H. van Loo P. Greenman C. Wedge D. et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400–404.
54. Telli M. Jensen K. Kurian A. Vinayak S. Lipson J. Schackmann E. et al. (2013) PRECOG 0105: final efficacy results from a phase ii study of gemicitabine and carboplatin plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer. J Clin Oncol 31: 1003.
55. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
56. Turner N. Moretti E. Siclari O. Migliaccio I. Santarpia L. D'Incalci M. et al. (2013) Targeting triple negative breast cancer: is P 53 the answer? Cancer Treat Rev 39: 541–550.
57. Tutt A. Robson M. Garber J. Domchek S. Audeh M. Weitzel J. et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA 1 or BRCA 2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235–244.
58. Vollebergh M. Lips E. Nederlof P. Wessels L. Schmidt M. van Beers E. et al. (2011) An ACGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22: 1561–1570.
59. von Minckwitz G. Muller B. Loibl S. Budczies J. Hanusch C. Darb-Esfahani S. et al. (2011) Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 29: 2150–2157.
60. Yunokawa M. Koizumi F. Kitamura Y. Katanasaka Y. Okamoto N. Kodaira M. et al. (2012) Efficacy of everolimus, a novel MTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 103: 1665–1671.